Clinical Trial Update: Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating alprostadil gel (FemLife Gel) for female sexual arousal disorder was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Female Sexual Arousal Disorder

Drugs mentioned

• FemLife Gel (alprostadil)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Female Sexual Arousal Disorder | Phase 1 | Status: TERMINATED